ID

22150

Beschreibung

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00694603

Link

https://clinicaltrials.gov/show/NCT00694603

Stichworte

Versionen (1)
  1. 21.05.17 21.05.17 -
Hochgeladen am

21. Mai 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-small Cell Lung Cancer NCT00694603

Englisch

Eligibility Non-small Cell Lung Cancer NCT00694603

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
pathologically confirmed stage iiib or iv recurrent or progressive nsclc
Beschreibung

nsclc stage

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0178759
patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the egfr pathway
Beschreibung

disease progression while egfr tyrosine kinase inhibitor

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0242656
UMLS CUI [1,2]
C1443775
measurable disease, as defined by recist criteria
Beschreibung

recist criteria

Datentyp

boolean

Alias
UMLS CUI [1]
C1709926
patients must have a suitable frozen or paraffin-embedded tissue sample available for egfr mutational analysis. prior egfr mutational analyses are allowable
Beschreibung

egfr mutational status

Datentyp

boolean

Alias
UMLS CUI [1]
C3266973
patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable
Beschreibung

asymptomatic brain metastasis, radiotherapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231221
UMLS CUI [1,3]
C1522449
ecog performance status 0-2
Beschreibung

ecog

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
18 years of age or older
Beschreibung

age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential
Beschreibung

pregnancy test

Datentyp

boolean

Alias
UMLS CUI [1]
C0032976
bone marrow function, renal function, hepatic function as outlined in protocol
Beschreibung

bone marrow, renal, hepatic function

Datentyp

boolean

Alias
UMLS CUI [1]
C0005953
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
women who are pregnant of breastfeeding
Beschreibung

pregnancy, breast feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
active concurrent malignancy
Beschreibung

concurrent malignancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab
Beschreibung

major surgery

Datentyp

boolean

Alias
UMLS CUI [1]
C0679637
significant history of uncontrolled cardiac disease
Beschreibung

cardiac disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0018799
uncontrolled seizure disorder, or active neurological disease
Beschreibung

seizure disorder, neurological disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0014544
UMLS CUI [2]
C0027765
prior severe infusion reactions to a monoclonal antibody
Beschreibung

monoclonal antibodies adverse event

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0003250
UMLS CUI [1,2]
C0877248
prior chemotherapy regimen within 21 days prior to study entry
Beschreibung

chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0392920
any egfr tyrosine kinase inhibitor within 14 days of study entry
Beschreibung

egfr tyrosine kinase inhibitors

Datentyp

boolean

Alias
UMLS CUI [1]
C1443775
radiation therapy within 14 days prior to the first infusion of cetuximab
Beschreibung

radiotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C1522449
acute hepatitis or known hiv
Beschreibung

acute hepatitis, hiv

Datentyp

boolean

Alias
UMLS CUI [1]
C0267797
UMLS CUI [2]
C0019682
active or uncontrolled infection
Beschreibung

infection

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450
any concurrent chemotherapy or any other investigational agent(s)
Beschreibung

concurrent chemotherapy, investigational agents

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0009429
UMLS CUI [2]
C0013230
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-small Cell Lung Cancer NCT00694603

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
nsclc stage
Item
pathologically confirmed stage iiib or iv recurrent or progressive nsclc
boolean
C0007131 (UMLS CUI [1,1])
C0178759 (UMLS CUI [1,2])
disease progression while egfr tyrosine kinase inhibitor
Item
patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the egfr pathway
boolean
C0242656 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
recist criteria
Item
measurable disease, as defined by recist criteria
boolean
C1709926 (UMLS CUI [1])
egfr mutational status
Item
patients must have a suitable frozen or paraffin-embedded tissue sample available for egfr mutational analysis. prior egfr mutational analyses are allowable
boolean
C3266973 (UMLS CUI [1])
asymptomatic brain metastasis, radiotherapy
Item
patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable
boolean
C0220650 (UMLS CUI [1,1])
C0231221 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,3])
ecog
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
pregnancy test
Item
negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential
boolean
C0032976 (UMLS CUI [1])
bone marrow, renal, hepatic function
Item
bone marrow function, renal function, hepatic function as outlined in protocol
boolean
C0005953 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
pregnancy, breast feeding
Item
women who are pregnant of breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
concurrent malignancy
Item
active concurrent malignancy
boolean
C0006826 (UMLS CUI [1])
major surgery
Item
major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab
boolean
C0679637 (UMLS CUI [1])
cardiac disease
Item
significant history of uncontrolled cardiac disease
boolean
C0018799 (UMLS CUI [1])
seizure disorder, neurological disease
Item
uncontrolled seizure disorder, or active neurological disease
boolean
C0014544 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
monoclonal antibodies adverse event
Item
prior severe infusion reactions to a monoclonal antibody
boolean
C0003250 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
chemotherapy
Item
prior chemotherapy regimen within 21 days prior to study entry
boolean
C0392920 (UMLS CUI [1])
egfr tyrosine kinase inhibitors
Item
any egfr tyrosine kinase inhibitor within 14 days of study entry
boolean
C1443775 (UMLS CUI [1])
radiotherapy
Item
radiation therapy within 14 days prior to the first infusion of cetuximab
boolean
C1522449 (UMLS CUI [1])
acute hepatitis, hiv
Item
acute hepatitis or known hiv
boolean
C0267797 (UMLS CUI [1])
C0019682 (UMLS CUI [2])
infection
Item
active or uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
concurrent chemotherapy, investigational agents
Item
any concurrent chemotherapy or any other investigational agent(s)
boolean
C0392920 (UMLS CUI [1,1])
C0009429 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video